The "Fast Money" traders share their final trades of the day.» Read More
Actavis agreed to acquire rival drug maker Forest Laboratories in a deal worth as much as $25 billion.
Some of Thursday's midday movers:
Markets are in wait-and-see mode ahead of Friday's jobs report, but there are a few events Thursday that could sway the market's direction.
Talking Squawk, the "Squawk Box" blog, provides tidbits, insights and sarcastic reflections on the WEEK THAT WAS and the WEEK TO COME.
Some of Wednesday's midday movers:
Sanofi's Lemtrada multiple sclerosis treatment has failed to win approval from U.S. regulators, dealing a setback to a drug which was at the heart of the French drugmaker's $20 billion takeover of biotech firm Genzyme.
Take a look at some of Friday's midday movers: Twitter, Textron, Sprint
Some of the names on the move ahead of the open.
Jim Cramer often advocates viewing a sell-off as opportunity. Often, but not always.
Take a look at some of Wednesday's midday movers:
Take a look at some of Monday's midday movers:
GlaxoSmithKline's pharmaceutical and vaccine sales to China tumbled 61 percent in the third quarter, with the drugmaker hit by an ongoing bribery investigation.
The economy may have added as many as 200,000 jobs in July amid the backdrop of a pickup in manufacturing activity and fewer layoffs.
Check out which companies are making headlines after the bell Thursday:
Traders are looking past ISM manufacturing data and weekly jobless claims, to the July nonfarm payrolls because it will be key in the Fed's decision making process.
It’s time for the Lightning Round. Cramer makes the call on viewer favorites.
The "Fast Money" traders share their final trades of the day.
Check out which companies are making headlines after the bell Tuesday:
Stocks finished near session lows in choppy trading Wednesday, with the Dow posting its first three-day losing streak this year, amid lingering worries of Fed tapering.
Pfizer announced a $2.15 billion settlement from Teva Pharmaceuticals and and Sun Pharmaceutical for patent infringement on its drug Protonix.